Certolizumab Pegol is Associated with Long-Term Improvements in Patient-Reported Outcomes in Axial Spondyloarthritis Patients, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis- 4-Year Outcomes from the Rapid-Axs ...
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1430
https://www.valueinhealthjournal.com/article/S1098-3015(16)32796-6/fulltext
Title :
Certolizumab Pegol is Associated with Long-Term Improvements in Patient-Reported Outcomes in Axial Spondyloarthritis Patients, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis- 4-Year Outcomes from the Rapid-Axs ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32796-6&doi=10.1016/j.jval.2016.09.1430
First page :
A595
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1347